{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:07:39Z","timestamp":1790802459667,"version":"4.1.0"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Fetal Growth Restriction (FGR) affects up to 10% of pregnancies and is linked to perinatal morbidity and mortality. This review summarizes current and emerging therapies aimed at preventing and treating placental-mediated FGR. Low-dose aspirin initiated before 16 weeks shows the strongest evidence for benefit. Low-molecular-weight heparin and other interventions\u2014including phosphodiesterase-5 inhibitors, statins, nitric oxide donors, VEGF gene therapy, melatonin, and IGF-based strategies\u2014remain investigational. Given shared pathophysiology with preeclampsia, FGR presents an opportunity for early intervention. Future efforts must focus on risk stratification and development of targeted therapies to improve placental function and fetal outcomes.<\/jats:p>","DOI":"10.1097\/grf.0000000000000971","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T11:07:25Z","timestamp":1760353645000},"page":"550-557","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Fetal Growth Restriction Prevention"],"prefix":"10.1097","volume":"68","author":[{"given":"Joanne","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"R1-20251023","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.placenta.2015.03.003","article-title":"Animal models of fetal growth restriction: considerations for translational medicine","volume":"36","author":"Swanson","year":"2015","journal-title":"Placenta"},{"issue":"1 Pt 1","key":"R2-20251023","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0002-9378(00)70513-8","article-title":"Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. The Vermont Oxford Network","volume":"182","author":"Bernstein","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"R3-20251023","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1471-2393-14-63","article-title":"Fetal growth restriction and the risk of perinatal mortality-case studies from the multicentre PORTO study","volume":"14","author":"Unterscheider","year":"2014","journal-title":"BMC Pregnancy Childbirth"},{"key":"R4-20251023","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.ajog.2005.10.816","article-title":"Customized versus population-based birth weight standards for identifying growth restricted infants: a French multicenter study","volume":"194","author":"Ego","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"R5-20251023","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ajog.2006.09.017","article-title":"Risk factors for antepartum and intrapartum stillbirth: a population-based study","volume":"196","author":"Getahun","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"R6-20251023","doi-asserted-by":"crossref","first-page":"121.e1","DOI":"10.1016\/j.ajog.2012.05.011","article-title":"Cardiovascular programming in children born small for gestational age and relationship with prenatal signs of severity","volume":"207","author":"Crispi","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"2S","key":"R7-20251023","doi-asserted-by":"crossref","first-page":"S869","DOI":"10.1016\/j.ajog.2017.12.012","article-title":"Long-term cardiovascular consequences of fetal growth restriction: biology, clinical implications, and opportunities for prevention of adult disease","volume":"218","author":"Crispi","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"R8-20251023","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/AOG.0000000000004350","article-title":"ACOG Practice Bulletin No. 227: Fetal Growth Restriction: Correction","volume":"137","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R9-20251023","doi-asserted-by":"crossref","first-page":"B2","DOI":"10.1016\/j.ajog.2020.05.010","article-title":"Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline Number 3, April 2012)","volume":"223","author":"Martins","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"R10-20251023","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/uog.15884","article-title":"Consensus definition of fetal growth restriction: a Delphi procedure","volume":"48","author":"Gordijn","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"2S","key":"R11-20251023","doi-asserted-by":"crossref","first-page":"S745","DOI":"10.1016\/j.ajog.2017.11.577","article-title":"Pathophysiology of placental-derived fetal growth restriction","volume":"218","author":"Burton","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"R12-20251023","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1053\/plac.2001.0700","article-title":"Villous trophoblast: morphometric perspectives on growth, differentiation, turnover and deposition of fibrin-type fibrinoid during gestation","volume":"22","author":"Mayhew","year":"2001","journal-title":"Placenta"},{"issue":"suppl A","key":"R13-20251023","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.placenta.2007.09.003","article-title":"Placental pathology: a systematic approach with clinical correlations","volume":"29","author":"Redline","year":"2008","journal-title":"Placenta"},{"key":"R14-20251023","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1515\/jpm.2010.041","article-title":"Fetal growth restriction - from observation to intervention","volume":"38","author":"Baschat","year":"2010","journal-title":"J Perinat Med"},{"key":"R15-20251023","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1089\/152702901750265341","article-title":"Human genetic adaptation to high altitude","volume":"2","author":"Moore","year":"2001","journal-title":"High Alt Med Biol"},{"key":"R16-20251023","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijheh.2016.05.001","article-title":"Environmental pollutants and child health-a review of recent concerns","volume":"219","author":"Vrijheid","year":"2016","journal-title":"Int J Hyg Environ Health"},{"key":"R17-20251023","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.placenta.2005.12.006","article-title":"The uterine spiral arteries in human pregnancy: facts and controversies","volume":"27","author":"Pijnenborg","year":"2006","journal-title":"Placenta"},{"issue":"suppl A","key":"R18-20251023","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.placenta.2008.11.021","article-title":"Placental stress and pre-eclampsia: a revised view","volume":"30","author":"Redman","year":"2009","journal-title":"Placenta"},{"key":"R19-20251023","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJMoa055352","article-title":"Soluble endoglin and other circulating antiangiogenic factors in preeclampsia","volume":"355","author":"Levine","year":"2006","journal-title":"N Engl J Med"},{"issue":"2S","key":"R20-20251023","doi-asserted-by":"crossref","first-page":"S803","DOI":"10.1016\/j.ajog.2017.11.575","article-title":"A placenta clinic approach to the diagnosis and management of fetal growth restriction","volume":"218","author":"Kingdom","year":"2018","journal-title":"Am J Obstet Gynecol"},{"issue":"2 Pt 1","key":"R21-20251023","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/AOG.0b013e3181e9322a","article-title":"Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis","volume":"116","author":"Bujold","year":"2010","journal-title":"Obstet Gynecol"},{"key":"R22-20251023","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajog.2016.09.076","article-title":"The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis","volume":"216","author":"Roberge","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R23-20251023","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ajog.2016.10.016","article-title":"Antiplatelet therapy before or after 16 weeks\u2019 gestation for preventing preeclampsia: an individual participant data meta-analysis","volume":"216","author":"Meher","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R24-20251023","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N Engl J Med"},{"key":"R25-20251023","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1515\/jpm-2017-0184","article-title":"Low dose aspirin for preventing fetal growth restriction: a randomised trial","volume":"46","author":"Stanescu","year":"2018","journal-title":"J Perinat Med"},{"key":"R26-20251023","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/S0140-6736(16)31139-4","article-title":"Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials","volume":"388","author":"Rodger","year":"2016","journal-title":"Lancet"},{"key":"R27-20251023","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/AOG.0000000000001673","article-title":"Enoxaparin and aspirin compared with aspirin alone to prevent placenta-mediated pregnancy complications: a randomized controlled trial","volume":"128","author":"Haddad","year":"2016","journal-title":"Obstet Gynecol"},{"key":"R28-20251023","doi-asserted-by":"crossref","first-page":"296.e1","DOI":"10.1016\/j.ajog.2017.01.014","article-title":"Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial","volume":"216","author":"Groom","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"2S","key":"R29-20251023","doi-asserted-by":"crossref","first-page":"S829","DOI":"10.1016\/j.ajog.2017.11.565","article-title":"The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction","volume":"218","author":"Groom","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"R30-20251023","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1210\/jc.2004-1831","article-title":"Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction","volume":"90","author":"Wareing","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R31-20251023","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/nature06951","article-title":"Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia","volume":"453","author":"Kanasaki","year":"2008","journal-title":"Nature"},{"key":"R32-20251023","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/HYPERTENSIONAHA.111.186270","article-title":"Sildenafil citrate rescues fetal growth in the catechol-O-methyl transferase knockout mouse model","volume":"59","author":"Stanley","year":"2012","journal-title":"Hypertension"},{"key":"R33-20251023","doi-asserted-by":"crossref","first-page":"102.e1","DOI":"10.1016\/j.ajog.2008.08.029","article-title":"The effects of sildenafil citrate (Viagra) on uterine blood flow and well being in the intrauterine growth-restricted fetus","volume":"200","author":"Miller","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"R34-20251023","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1055\/s-0032-1304823","article-title":"Effects of sildenafil in N\u03c9-nitro-L-arginine methyl ester-induced intrauterine growth restriction in a rat model","volume":"29","author":"Nassar","year":"2012","journal-title":"Am J Perinatol"},{"key":"R35-20251023","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/10641950802601278","article-title":"A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia","volume":"28","author":"Samangaya","year":"2009","journal-title":"Hypertens Pregnancy"},{"key":"R36-20251023","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/AOG.0000000000001518","article-title":"Perinatal and hemodynamic evaluation of sildenafil citrate for preeclampsia treatment: a randomized controlled trial","volume":"128","author":"Trapani","year":"2016","journal-title":"Obstet Gynecol"},{"key":"R37-20251023","first-page":"632","article-title":"Sildenafil citrate and uteroplacental perfusion in fetal growth restriction","volume":"17","author":"Dastjerdi","year":"2012","journal-title":"J Res Med Sci"},{"key":"R38-20251023","article-title":"STRIDER UK: a randomized controlled trial of sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction","author":"Alfirevic","year":"2016","journal-title":"Zenodo"},{"key":"R40-20251023","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/s12884-023-05747-7","article-title":"The effects of sildenafil citrate on intrauterine growth restriction: a systematic review an meta-analysis","volume":"23","author":"Rakhanova","year":"2023","journal-title":"BMC Pregnancy Childbirth"},{"key":"R41-20251023","first-page":"CD014498","article-title":"Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy","volume":"7","author":"Pels","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"R42-20251023","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/gt.2008.102","article-title":"Local delivery of VEGF adenovirus to the uterine artery increases vasorelaxation and uterine blood flow in the pregnant sheep","volume":"15","author":"David","year":"2008","journal-title":"Gene Ther"},{"key":"R43-20251023","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/gt.2011.158","article-title":"Long-term increase in uterine blood flow is achieved by local overexpression of VEFF-A(165) in the uterine arteries of pregnant sheep","volume":"19","author":"Mehta","year":"2012","journal-title":"Gene Ther"},{"key":"R44-20251023","doi-asserted-by":"crossref","first-page":"e100021","DOI":"10.1371\/journal.pone.0100021","article-title":"Local over-expression of VEGF-DDeltaNDeltaC in the uterine arteries of pregnant sheep results in long-term changes in uterine artery contractility and angiogenesis","volume":"9","author":"Mehta","year":"2014","journal-title":"PLoS One"},{"key":"R45-20251023","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s43032-024-01604-w","article-title":"Maternal uterine artery adenoviral vascular endothelial growth factor (Ad.VEGF-A165) gene therapy normalizes fetal brain growth and microglial activation in nutrient restricted pregnant guinea pigs","volume":"31","author":"Hristova","year":"2024","journal-title":"Reprod Sci"},{"key":"R46-20251023","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12884-017-1226-7","article-title":"EVERREST prospective study: a 6-year prospective study to define the clinical and biological characteristics of pregnancies affected by severe early onset fetal growth restriction","volume":"17","author":"Spencer","year":"2017","journal-title":"BMC Pregnancy Childbirth"},{"key":"R47-20251023","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1161\/HYPERTENSIONAHA.111.00226","article-title":"Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension","volume":"61","author":"Bauer","year":"2013","journal-title":"Hypertension"},{"key":"R48-20251023","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/AOG.0b013e3181e10ebd","article-title":"Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia","volume":"116","author":"Constantine","year":"2010","journal-title":"Obstet GYnecol"},{"key":"R49-20251023","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.3390\/biomedicines11102685","article-title":"The effects of prenatal pravastatin treatment in the rabbit fetal growth restriction model","volume":"11","author":"Zapletalova","year":"2023","journal-title":"Biomedicines"},{"key":"R50-20251023","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1055\/s-0040-1713651","volume":"38","author":"Mendoza","year":"2021","journal-title":"Am J Perinatol"},{"key":"R51-20251023","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejogrb.2023.01.036","article-title":"Pravastatin for severe preeclampsia with growth restriction","volume":"283","author":"Fruci","year":"2023","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R52-20251023","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"R53-20251023","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/biom9050166","article-title":"Maternal metformin treatment improves developmental and metabolic traits of IUGR fetuses","volume":"9","author":"Garcia-Contreras","year":"2019","journal-title":"Biomolecules"},{"key":"R54-20251023","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1056\/NEJM199508313330903","article-title":"Metabolic effects of metformin in non-insulin-dependent diabetes","volume":"333","author":"Stumvoll","year":"1995","journal-title":"N Engl J Med"},{"key":"R55-20251023","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/ijms19010293","article-title":"Proangiogenic effects of metformin in endothelial cells is via upregulation of VEGFR1\/2 and their signaling under hyperglycemia-hypoxia","volume":"19","author":"Bakhashab","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R56-20251023","doi-asserted-by":"crossref","first-page":"150996","DOI":"10.1016\/j.bbrc.2024.150996","article-title":"Protective effect of metformin on the NG-nitro-1-arginine methyl ester (l-NAME)-induced rat models of preeclampsia","volume":"739","author":"Hao","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"R57-20251023","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.trsl.2020.08.002","article-title":"Treatment of pregnancies complicated by intrauterine growth restriction with nitric oxide donors increases placental expression of Epidermal Growth Factor-Like Domain 7 and improves fetal growth: a pilot study","volume":"228","author":"Massimiani","year":"2021","journal-title":"Transl Res"},{"key":"R58-20251023","doi-asserted-by":"crossref","first-page":"84.e1","DOI":"10.1016\/j.ajog.2022.07.028","article-title":"Effect of pentaerythritol tetranitrate (PETN) on the development of fetal growth restriction in pregnancies with impaired uteroplacental perfusion at midgestation\u2013 a randomized trial","volume":"228","author":"Groten","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"R59-20251023","first-page":"100350","article-title":"Pentaerithrityl tetranitrate (PETN) for prevention of fetal growth restriction in pregnancy: a systematic review and meta-analysis","volume":"24","author":"Heda","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol X"},{"key":"R60-20251023","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/jas\/sky443","article-title":"Rapid Communication: maternal melatonin implants improve fetal oxygen supply and body weight at term in sheep pregnancies","volume":"97","author":"Sales","year":"2019","journal-title":"J Anim Sci"},{"key":"R61-20251023","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/jpi.12121","article-title":"Antenatal antioxidant treatment with melatonin to decrease newborn neurodevelopmental deficits and brain injury caused by fetal growth restriction","volume":"56","author":"Miller","year":"2014","journal-title":"J Pineal Res"},{"key":"R62-20251023","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bpobgyn.2018.02.007","article-title":"Prophylaxis and treatment of foetal growth restriction","volume":"49","author":"Nawathe","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R63-20251023","doi-asserted-by":"crossref","first-page":"e74632","DOI":"10.1371\/journal.pone.0074632","article-title":"Adenoviral-mediated placental gene transfer of IGF-1 corrects placental insufficiency via enhanced placental glucose transport mechanisms","volume":"8","author":"Jones","year":"2013","journal-title":"PLoS One"},{"key":"R64-20251023","doi-asserted-by":"crossref","first-page":"9079","DOI":"10.1038\/s41598-017-06300-1","article-title":"Treating the placenta to prevent adverse effects of gestational hypoxia on the brain development","volume":"7","author":"Phillips","year":"2017","journal-title":"Sci Rep"},{"key":"R65-20251023","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.7150\/thno.18845","article-title":"Placental homing peptide-microRNA inhibitor conjugates for targeted enhancement of intrinsic placental growth signaling","volume":"7","author":"Beards","year":"2017","journal-title":"Theranostics"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000971","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:01:14Z","timestamp":1761224474000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000971"}},"subtitle":["Is There a Role for Aspirin, Heparin, Statins, and Others?"],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000971","relation":{},"ISSN":["0009-9201","1532-5520"],"issn-type":[{"value":"0009-9201","type":"print"},{"value":"1532-5520","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]}}}